We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+16.35%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$239M
AUM Growth
-$103M
Cap. Flow
-$106M
Cap. Flow %
-44.2%
Top 10 Hldgs %
35.32%
Holding
114
New
39
Increased
6
Reduced
19
Closed
45

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.8M
2
HCA icon
HCA Healthcare
HCA
+$3.62M
3
HOLX
Hologic
HOLX
+$3.59M
4
ZGNX
Zogenix, Inc.
ZGNX
+$3.47M
5
MDT icon
Medtronic
MDT
+$3M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$9.9M
2
CNC icon
Centene
CNC
+$7.74M
3
AGN
Allergan plc
AGN
+$7.17M
4
DXCM icon
DexCom
DXCM
+$6.24M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$6.22M

Sector Composition

Rank Sector Weight
1 Healthcare 46.43%
2 Industrials 2.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIEN
101
DELISTED
Sientra, Inc.
SIEN
– –
-18,780
Closed -$2.89M
NSTG
102
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-275,000
Closed -$2.61M
AGRX
103
DELISTED
Agile Therapeutics
AGRX
– –
-145
Closed -$1.29M
AERI
104
PUT
DELISTED
Aerie Pharmaceuticals
AERI
– –
-35,200
Closed -$1.71M
ADMS
105
CALL
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-200,000
Closed -$4.23M
PRAH
106
DELISTED
PRA Health Sciences, Inc.
PRAH
– –
-45,000
Closed -$3.43M
FPRX
107
CALL
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-75,000
Closed -$3.07M
NBRV
108
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-1,700
Closed -$3.48M
STML
109
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-60,000
Closed -$666K
AGN
110
DELISTED
Allergan plc
AGN
– –
-35,000
Closed -$7.17M
ONCE
111
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-37,589
Closed -$3.35M
SGYP
112
CALL
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-100,000
Closed -$290K
ESRX
113
CALL
DELISTED
Express Scripts Holding Company
ESRX
– –
-15,000
Closed -$950K
ZGNX
114
CALL
DELISTED
Zogenix, Inc.
ZGNX
– –
-62,600
Closed -$2.19M
1 2 3 4
5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
ONGA
O'Neil Global Advisors Los Angeles, California $14.4M AUM 220.73% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM

Pura Vida Investments's Q4 2017 Portfolio in Review

As of Q4 2017, Pura Vida Investments held 114 positions worth $239M, down 30% from $342M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Pura Vida Investments withdrew a net $106M in Q4 2017, closing 45 positions and reducing 19 holdings. Its most notable exit was Merck, an estimated $9.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 50% a quarter earlier, followed by Industrials.

Against the trend, Pura Vida Investments opened a new position in BioMarin Pharmaceuticals worth $3.9M.

  • Pura Vida Investments's largest Q4 2017 buy was BioMarin Pharmaceuticals: 43,700 shares worth $3.9M.
  • Pura Vida Investments added most to Zogenix, Inc. in Q4 2017, an estimated $3.47M increase.
  • Pura Vida Investments's biggest Q4 2017 reduction was LivaNova, cutting an estimated $5.1M.
  • Pura Vida Investments fully exited Merck in Q4 2017, selling an estimated $9.9M.
  • Pura Vida Investments's ten largest holdings make up 35% of its $239M portfolio in Q4 2017.
  • Pura Vida Investments opened 39 new positions and closed 45 in Q4 2017.
  • Pura Vida Investments's portfolio value fell 30% quarter-over-quarter to $239M.

Based on Pura Vida Investments's 13F filing for Q4 2017, filed 14 Feb 2018.